Therapeutic task force on enhanced half-life products

Membership

Peter Collins	Chairman
Elizabeth Chalmers	
Pratima Chowdary	
David Keeling	
Mary Mathias	
James O'Donnell	
John Pasi	
Savita Rangarajan	
Angela Thomas	

Meetings

A document was developed by email and teleconference

Aims

1. To write pragmatic advice on the use of enhanced half-life products in haemophilia A and B in UK.
2. To discuss tendering options to put forward to UKHCDO for consideration

It is recognised that published evidence is evolving rapidly.

Areas to cover in document

1. Background of products and technologies
2. Treatment strategy when switching to enhanced half-life products
3. Management of previously untreated patients and minimally treated patients
4. Management of bleeds
5. Prophylaxis
6. Surgery
7. Laboratory monitoring
8. Advice to UKHCDO regarding adverse event reporting through NHD

Each area will consider issues specific to individual products and the implications of age.

Current position:

Document is completed and has been published, Haemophilia 22:487-98, 2016.

The document helped to inform the tendering exercise during 2016.

The document underpins the English Clinical Reference Group "Criteria for the Prescribing of Enhanced Half-Life Blood Factors".

The Taskforce has been disbanded.

Professor Peter Collins
Chairman, Therapeutics Task Force
September 2016